Company Search:
Advanced Search
Sponsored Links
Intervacc AB Company Snapshot
Intervacc AB operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Intervacc AB with three other companies in this sector in SWEDEN : Active Biotech AB (publ) (2019 sales of 8.43 million Swedish Kronor [US$952,109.25 ] of which 58% was Rental revenues), ArcAroma AB (7.96 million Swedish Kronor [US$899,902.92 ] ), and Medivir AB (8.72 million Swedish Kronor [US$985,899.24 ] of which 100% was Pharmaceutical).

Sales Analysis. Intervacc AB reported sales of SEK 12.14 million (US$1.37 million) for the year ending December of 2019. This represents a sharp decrease of 65.9% versus 2018, when the company's sales were SEK 35.60 million.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Intervacc AB
  Stock Performance Chart for Intervacc AB
  Stock Data: Recent Stock Performance:
  Current Price (10/23/2020): 49.90
(Figures in Swedish Kronor)
1 Week -7.4%   13 Weeks 23.8%  
4 Weeks 57.4%   52 Weeks 118.9%  
Intervacc AB Key Data:
  Ticker: IVACC Country: Sweden
  Exchanges: STO Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2019 Sales 12,139,000
(Year Ending Jan 2020).
Employees: 15
  Currency: Swedish Kronor Market Cap: 2,501,210,704
  Fiscal Yr Ends: December Shares Outstanding: 50,124,463
  Share Type: Aktie Closely Held Shares:
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.